Peter Gennemark

Adjunct Associate Professor

Linköping University

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Gennemark is an Adjunct Associate Professor at Linköping University, Sweden. His research focuses on the fields of pharmacokinetics, molecular communication, and computational modeling, with recent publications addressing siRNA delivery, liver steatosis dynamics, and diabetes research. His innovative work encompasses both theoretical frameworks and practical applications in drug development and nutrition.

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Cristina Rocha

Professor Adjunto Convidado

Polytechnic Institute of Porto

PORTUGAL

View details

Ingrid Hotz

Professor

Linköping University

SWEDEN

View details

Adam Noel

University of Warwick

UNITED KINGDOM

View details

Karin G. Stenkula

Lund University

SWEDEN

View details

Rasmus Magnusson

University of Skövde

SWEDEN

View details

Peter Lundberg

Linköping University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Gennemark

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery

A unified framework for prediction of liver steatosis dynamics in response to different diet and drug interventions

Spheroidal Molecular Communication via Diffusion: Signaling Between Homogeneous Cell Aggregates

Tissue pharmacokinetics of antisense oligonucleotides

A multi-scale in silico mouse model for diet-induced insulin resistance

Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)

Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs

Integrated experimental-computational analysis of a HepaRG liver-islet microphysiological system for human-centric diabetes research

A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.

Digital twin predicting diet response before and after long-term fasting

Inhibition of SGLT2 Preserves Function and Promotes Proliferation of Human Islets Cells In Vivo in Diabetic Mice.

An oral antisense oligonucleotide for PCSK9 inhibition

Mathematical Model Predicts that Acceleration of Diabetic Wound Healing is Dependent on Spatial Distribution of VEGF-A mRNA (AZD8601).

Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.

Hybrid modelling for stroke care: Review and suggestions of new approaches for risk assessment and simulation of scenarios

Collaborators (6)

Cristina Rocha

Ingrid Hotz

Adam Noel

Karin G. Stenkula

Rasmus Magnusson

Peter Lundberg

Make your next move.